MX348637B - Anticuerpos y composiciones anti-her3. - Google Patents

Anticuerpos y composiciones anti-her3.

Info

Publication number
MX348637B
MX348637B MX2013004897A MX2013004897A MX348637B MX 348637 B MX348637 B MX 348637B MX 2013004897 A MX2013004897 A MX 2013004897A MX 2013004897 A MX2013004897 A MX 2013004897A MX 348637 B MX348637 B MX 348637B
Authority
MX
Mexico
Prior art keywords
compositions
antibodies
her3 antibodies
her3
recombinant
Prior art date
Application number
MX2013004897A
Other languages
English (en)
Other versions
MX2013004897A (es
Inventor
Koefoed Klaus
Wandahl Pedersen Mikkel
Jacobsen Helle
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2013004897A publication Critical patent/MX2013004897A/es
Publication of MX348637B publication Critical patent/MX348637B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los nuevos anticuerpos recombinantes terapéuticos dirigidos contra HER34 (ErbB3), así como las composiciones que comprenden las mezclas de al menos dos de los anticuerpos recombinantes anti-HER3, y el uso de los anticuerpos y las combinaciones de anticuerpo para el tratamiento del cáncer.
MX2013004897A 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3. MX348637B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
PCT/IB2011/054835 WO2012059858A1 (en) 2010-11-01 2011-10-31 Anti-her3 antibodies and compositions

Publications (2)

Publication Number Publication Date
MX2013004897A MX2013004897A (es) 2013-07-15
MX348637B true MX348637B (es) 2017-06-22

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.

Country Status (13)

Country Link
US (1) US9217039B2 (es)
EP (3) EP2635604B1 (es)
JP (2) JP6033783B2 (es)
KR (2) KR101773120B1 (es)
AU (2) AU2011324871B2 (es)
CA (2) CA2816519C (es)
DK (1) DK2635604T3 (es)
ES (2) ES2692379T3 (es)
IL (2) IL225954B (es)
MX (2) MX348637B (es)
PL (1) PL2635604T3 (es)
TW (1) TW201231066A (es)
WO (2) WO2012059858A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706255B1 (ko) * 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
MY161909A (en) 2009-12-22 2017-05-15 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP2635604B1 (en) 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
BR112013022887A2 (pt) * 2011-03-15 2016-12-06 Merrimack Pharmaceuticals Inc superação de resistência a inibidores de via de erbb
WO2012156975A1 (en) * 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
SI2837680T1 (sl) * 2011-07-01 2020-07-31 Amgen Inc. Celična kultura sesalca
RU2620068C2 (ru) 2011-11-23 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные по отношению к her3, и их применения
US20130259867A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AU2013255537B2 (en) 2012-05-02 2018-02-15 Symphogen A/S Humanized pan-her antibody compositions
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3508502B1 (en) * 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
CA2959716A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
PE20191741A1 (es) 2017-04-05 2019-12-12 Symphogen As Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
EP3847194A1 (en) * 2018-09-07 2021-07-14 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
BR112021016094A2 (pt) * 2019-02-14 2021-10-26 Merus N.V. Combinações de porções de ligação que se ligam ao egfr, her2 e her3
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3206883A1 (en) 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PT896586E (pt) * 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ATE548657T1 (de) 2004-07-20 2012-03-15 Symphogen As Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie
KR20070038557A (ko) 2004-07-22 2007-04-10 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JP2008523073A (ja) 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
EP3248617A3 (en) * 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
DK2132229T3 (en) 2007-03-01 2016-06-20 Symphogen As Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
BRPI0820221A2 (pt) 2007-11-22 2015-05-26 Symphogen As Método para caracterização de uma proteína policlonal recombinante
CA2722348A1 (en) 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
US20110224094A1 (en) 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
TWI461211B (zh) * 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
JP5616428B2 (ja) * 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
EP2417159A1 (en) * 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
WO2010127181A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
ES2536996T3 (es) * 2009-07-06 2015-06-01 F. Hoffmann-La Roche Ag Anticuerpos biespecíficos de unión a digoxigenina
KR20120059568A (ko) 2009-08-21 2012-06-08 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
TWI630916B (zh) 2009-11-13 2018-08-01 第一三共歐洲公司 供治療或預防人表皮生長因子受體－３（ｈｅｒ－３）相關疾病之藥料和方法
TW201141519A (en) 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
ES2566602T3 (es) * 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
PT2606070T (pt) 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
EP2635604B1 (en) 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition

Also Published As

Publication number Publication date
AU2011324870B2 (en) 2015-01-29
AU2011324871B2 (en) 2016-05-19
AU2011324870A1 (en) 2013-01-31
CA2816520C (en) 2017-11-21
KR101862832B1 (ko) 2018-05-30
TW201231066A (en) 2012-08-01
CA2816519C (en) 2019-01-15
IL225953A0 (en) 2013-07-31
MX2013004897A (es) 2013-07-15
CA2816520A1 (en) 2012-05-10
KR101773120B1 (ko) 2017-08-30
IL225954B (en) 2018-05-31
DK2635604T3 (en) 2017-02-27
JP2014503188A (ja) 2014-02-13
JP6033783B2 (ja) 2016-11-30
EP3156421A1 (en) 2017-04-19
ES2616961T3 (es) 2017-06-14
PL2635604T3 (pl) 2017-09-29
KR20140026336A (ko) 2014-03-05
CA2816519A1 (en) 2012-05-10
WO2012059857A2 (en) 2012-05-10
JP2014503189A (ja) 2014-02-13
MX347981B (es) 2017-05-22
EP2635605A1 (en) 2013-09-11
MX2013004899A (es) 2013-07-15
US9217039B2 (en) 2015-12-22
AU2011324871A1 (en) 2013-05-09
KR20140026337A (ko) 2014-03-05
EP3156421B1 (en) 2018-06-06
EP2635605A4 (en) 2014-10-22
US20130287684A1 (en) 2013-10-31
WO2012059858A1 (en) 2012-05-10
WO2012059857A3 (en) 2012-07-19
EP2635604B1 (en) 2016-11-30
ES2692379T3 (es) 2018-12-03
EP2635605B1 (en) 2018-07-25
EP2635604A2 (en) 2013-09-11
IL225954A0 (en) 2013-07-31
JP6186277B2 (ja) 2017-08-23

Similar Documents

Publication Publication Date Title
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
PH12014502419A1 (en) Specific binding proteins and uses thereof
TN2015000396A1 (en) Antibody drug conjugates
MX2021001494A (es) Anticuerpos dkk1 y metodos de uso.
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2013002535A (es) Nuevas proteinas de union a antigenos.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EA201200999A1 (ru) Способы лечения рака молочной железы
MX357391B (es) Anticuerpos anti-erbb3 y usos de los mismos.
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201291065A1 (ru) Антитела против vla-4
MX346995B (es) Anticuerpos anti-notch1.
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
PH12015501360A1 (en) Bmp-6 antibodies
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.

Legal Events

Date Code Title Description
FG Grant or registration